CLAIM CARD
A second limitation is endpoint heterogeneity. Study-level signals span no dominant outcome class, the contextual adjacent evidence, safety and comorbidity, cardiometabolic outcome classes, the frailty outcome class, and no dominant outcome class; these domains cannot be pooled narratively without losing clinically relevant differences in measurement, population, and study design.
Evidence grade: exploratory
Contradiction status: none
Publication: 342e6c9b-631f-4021-99a2-d4eda568ae58
Provenance: Derivation Web chain
Citation Support
source_1Marco 2024source_2Yagi 2026source_3Barbaux 2025source_4Chan 2025source_5Lyu 2026